HHI therapy appeared to upregulate MHC class I expression and increase infiltrating immune cells (CD8+, CD4+, HLA-DR-class II+ mononuclear cells, and CD68+ macrophages) at the cancer site. The gene discussed is CD8A; the disease is cancer.